phosphorylcholine has been researched along with Niemann-Pick Disease, Type A in 3 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Niemann-Pick Disease, Type A: The classic infantile form of Niemann-Pick Disease, caused by mutation in SPHINGOMYELIN PHOSPHODIESTERASE. It is characterized by accumulation of SPHINGOMYELINS in the cells of the MONONUCLEAR PHAGOCYTE SYSTEM and other cell throughout the body leading to cell death. Clinical signs include JAUNDICE, hepatosplenomegaly, and severe brain damage.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The majority of adverse events were mild and included headache, nausea, and abdominal pain." | 2.87 | Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months. ( Diaz, GA; Ji, AJ; Jouvin, MH; Lachmann, RH; Nandy, I; Puga, AC; Wasserstein, MP, 2018) |
| "Acid sphingomyelinase deficiency (ASMd, Niemann-Pick disease A/B) and Niemann-Pick type C disease (NPC) share core clinical symptoms." | 1.46 | Quantitation of plasmatic lysosphingomyelin and lysosphingomyelin-509 for differential screening of Niemann-Pick A/B and C diseases. ( Asfaw, B; Gulinello, ME; Jahnova, H; Kuchar, L; Ledvinova, J; Lugowska, A; Malinova, V; Poupetova, H; Sikora, J, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wasserstein, MP | 1 |
| Diaz, GA | 1 |
| Lachmann, RH | 1 |
| Jouvin, MH | 1 |
| Nandy, I | 1 |
| Ji, AJ | 1 |
| Puga, AC | 1 |
| Kuchar, L | 1 |
| Sikora, J | 1 |
| Gulinello, ME | 1 |
| Poupetova, H | 1 |
| Lugowska, A | 1 |
| Malinova, V | 1 |
| Jahnova, H | 1 |
| Asfaw, B | 1 |
| Ledvinova, J | 1 |
| Chiulli, N | 1 |
| Codazzi, F | 1 |
| Di Cesare, A | 1 |
| Gravaghi, C | 1 |
| Zacchetti, D | 1 |
| Grohovaz, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Long-Term Study to Assess the Ongoing Safety and Efficacy of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency[NCT02004704] | Phase 2 | 25 participants (Actual) | Interventional | 2013-12-04 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for phosphorylcholine and Niemann-Pick Disease, Type A
| Article | Year |
|---|---|
Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months.
Topics: Adult; Biomarkers; Bone Density; Enzyme Replacement Therapy; Female; Hexosaminidases; Humans; Lipids | 2018 |
2 other studies available for phosphorylcholine and Niemann-Pick Disease, Type A
| Article | Year |
|---|---|
Quantitation of plasmatic lysosphingomyelin and lysosphingomyelin-509 for differential screening of Niemann-Pick A/B and C diseases.
Topics: Biomarkers; Case-Control Studies; Chromatography, Liquid; Dried Blood Spot Testing; Humans; Niemann- | 2017 |
Sphingosylphosphocholine effects on cultured astrocytes reveal mechanisms potentially involved in neurotoxicity in Niemann-Pick type A disease.
Topics: Animals; Apoptosis; Astrocytes; Cell Proliferation; Cells, Cultured; Cerebral Cortex; Fluorescent Dy | 2007 |